Microdose intravaginal levonorgestrel contraception: a multicentre clinical trial. II. Expulsions and removals. World Health Organization. Task Force on Long-Acting Systemic Agents for Fertility Regulation
- PMID: 2107055
- DOI: 10.1016/0010-7824(90)90142-i
Microdose intravaginal levonorgestrel contraception: a multicentre clinical trial. II. Expulsions and removals. World Health Organization. Task Force on Long-Acting Systemic Agents for Fertility Regulation
Abstract
This paper investigates the relationship between expulsions and removals, and demographic characteristics of 1005 women from 19 centres using a vaginal ring releasing 20 micrograms levonorgestrel per 24 hours. Emphasis is placed on discontinuations of method use due to expulsions, on the number and rate of expulsions, and the time at which the first expulsion occurred. The overall life-table discontinuation rate due to expulsion was 7.1% at one year. Life-table discontinuation rates increased with parity and were highest in Asian and lowest in European women. In respect to the number of expulsions experienced by women (expulsions did not necessarily lead to discontinuation), the women of high parity and those from Asia and Europe have the highest rates. The life-table first expulsion rate is 29% at one year. Such rates are highest in Chinese and Asian women. Following a first expulsion, the second expulsion rate is 45% by the end of the subsequent six months. The majority of first expulsions occur at defaecation (134 or 57% of 234 women), urination (12%) and during menstruation (17%). Rings were removed by 121 (12%) women on 201 occasions and for a variety of reasons. The main medical reasons were vaginal discharge and irritation, bleeding pain and dyspareunia. Others removed the ring during defaecation, intercourse or because the ring came out of place. Women also removed rings for curiosity, to show their husbands and to clean.
Similar articles
-
Microdose intravaginal levonorgestrel contraception: a multicentre clinical trial. I. Contraceptive efficacy and side effects. World Health Organization. Task Force on Long-Acting Systemic Agents for Fertility Regulation.Contraception. 1990 Feb;41(2):105-24. doi: 10.1016/0010-7824(90)90141-h. Contraception. 1990. PMID: 2107054 Clinical Trial.
-
Microdose intravaginal levonorgestrel contraception: a multicentre clinical trial. IV. Bleeding patterns. World Health Organization. Task Force on Long-Acting Systemic Agents for Fertility Regulation.Contraception. 1990 Feb;41(2):151-67. doi: 10.1016/0010-7824(90)90144-k. Contraception. 1990. PMID: 2107057 Clinical Trial.
-
Microdose intravaginal levonorgestrel contraception: a multicentre clinical trial. III. The relationship between pregnancy rate and body weight. World Health Organization. Task Force on Long-Acting Systemic Agents for Fertility Regulation.Contraception. 1990 Feb;41(2):143-50. doi: 10.1016/0010-7824(90)90143-j. Contraception. 1990. PMID: 2107056 Clinical Trial.
-
The ins and outs of drug-releasing vaginal rings: a literature review of expulsions and removals.Expert Opin Drug Deliv. 2020 Nov;17(11):1519-1540. doi: 10.1080/17425247.2020.1798927. Epub 2020 Aug 9. Expert Opin Drug Deliv. 2020. PMID: 32684013 Review.
-
Hormonal and intrauterine methods for contraception for women aged 25 years and younger.Cochrane Database Syst Rev. 2012 Nov 14;11:CD009805. doi: 10.1002/14651858.CD009805.pub2. Cochrane Database Syst Rev. 2012. Update in: Cochrane Database Syst Rev. 2015 Aug 17;(8):CD009805. doi: 10.1002/14651858.CD009805.pub3 PMID: 23152281 Updated. Review.
Cited by
-
Randomized, placebo controlled phase I trial of the safety, pharmacokinetics, pharmacodynamics and acceptability of a 90 day tenofovir plus levonorgestrel vaginal ring used continuously or cyclically in women: The CONRAD 138 study.PLoS One. 2022 Oct 10;17(10):e0275794. doi: 10.1371/journal.pone.0275794. eCollection 2022. PLoS One. 2022. PMID: 36215267 Free PMC article. Clinical Trial.
-
A 90-day tenofovir reservoir intravaginal ring for mucosal HIV prophylaxis.Antimicrob Agents Chemother. 2012 Dec;56(12):6272-83. doi: 10.1128/AAC.01431-12. Epub 2012 Sep 24. Antimicrob Agents Chemother. 2012. PMID: 23006751 Free PMC article.
-
Engineering a degradable polyurethane intravaginal ring for sustained delivery of dapivirine.Drug Deliv Transl Res. 2011 Jun;1(3):223-37. doi: 10.1007/s13346-011-0027-1. Drug Deliv Transl Res. 2011. PMID: 25788241
-
Hormonal contraceptives for contraception in overweight or obese women.Cochrane Database Syst Rev. 2016 Aug 18;2016(8):CD008452. doi: 10.1002/14651858.CD008452.pub4. Cochrane Database Syst Rev. 2016. PMID: 27537097 Free PMC article. Review.
-
Randomized, placebo controlled phase I trial of safety, pharmacokinetics, pharmacodynamics and acceptability of tenofovir and tenofovir plus levonorgestrel vaginal rings in women.PLoS One. 2018 Jun 28;13(6):e0199778. doi: 10.1371/journal.pone.0199778. eCollection 2018. PLoS One. 2018. PMID: 29953547 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical